Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03937791 · OUTCOME

Fraction of Participants With Vulvar High-Grade Squamous Intraepithelial Lesions (HSIL) Who Experience a Complete Response for E7 T-Cell Receptor (TCR) T Cells Treatment

Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions · Source last updated 2021-04-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Proportion of participants
Interval / dispersion
95% Confidence Interval
Time frame
3 months

What was measured

The fraction of patients who experience a complete response. Complete Response is disappearance of all target lesions. No appearance of new lesions.

Groups in this outcome

Arm 1/1x10^11 E7 T Cell Receptor (TCR) T Cells

1x10\^11 E7 TCR T cells will be administered intravenously over 20 to 30 minutes on day 0. E7 T Cell Receptor (TCR): One dose of E7 TCR T cells (1x10\^11 cells) will be administered intravenously over 20 to 30 minutes.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm 1/1x10^11 E7 T Cell Receptor (TCR) T Cells1

Reported measurements

Source class 1
Values in Proportion of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Arm 1/1x10^11 E7 T Cell Receptor (TCR) T Cells0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    units
    Participants
description
The fraction of patients who experience a complete response. Complete Response is disappearance of all target lesions. No appearance of new lesions.
dispersion Type
95% Confidence Interval
groups
  1. description
    1x10\^11 E7 TCR T cells will be administered intravenously over 20 to 30 minutes on day 0. E7 T Cell Receptor (TCR): One dose of E7 TCR T cells (1x10\^11 cells) will be administered intravenously over 20 to 30 minutes.
    id
    OG000
    title
    Arm 1/1x10^11 E7 T Cell Receptor (TCR) T Cells
param Type
NUMBER
reporting Status
POSTED
time Frame
3 months
title
Fraction of Participants With Vulvar High-Grade Squamous Intraepithelial Lesions (HSIL) Who Experience a Complete Response for E7 T-Cell Receptor (TCR) T Cells Treatment
type
PRIMARY
unit Of Measure
Proportion of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice